In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236

R. Sana (South San Francisco, United States of America), W. Krey-Epstein (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), S. Calhoun (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), J. Budman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America)

Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3872

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Sana (South San Francisco, United States of America), W. Krey-Epstein (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), S. Calhoun (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), J. Budman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America). In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236. 3872

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: